An update from Viva Biotech Holdings ( (HK:1873) ) is now available.
Viva Biotech Holdings has issued a positive profit alert, indicating a significant financial turnaround for the year ending December 31, 2024. The company expects to report a net profit between RMB210 million and RMB240 million, a notable improvement from the previous year’s net loss. This positive change is attributed to the substantial growth recovery of its CRO business, improved operational efficiency, and investment gains. The final audited financial results are expected to be published by the end of March 2025.
More about Viva Biotech Holdings
Viva Biotech Holdings is a company in the biotechnology industry, focusing on providing contract research organization (CRO) services. The company is involved in drug discovery and development, offering a range of services to pharmaceutical and biotech companies.
YTD Price Performance: 74.42%
Average Trading Volume: 5,446,536
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$3.22B
For a thorough assessment of 1873 stock, go to TipRanks’ Stock Analysis page.